• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

I need a response!

Anonymous

Guest
I work in big Pharma now but got contacted for a consulting position in IMS. What are the pros and cons of working for IMS vs Pharma? What is the pay like? Benefits?
 












Yeah, "practice area". How is that for pretentious? Would you really want to work for an outfit that uses terms like "practice area"? Imagine the meetings. "Here is a review of how 2007 ended, by practice area. You can see that Strategic Solutions without Pants, did better than Strategic Solutions with Pants, at least in the 4th quarter. However, look at what Strategic Mapping did for the year. This practice area defined itself and created a new paradigm for business gibberish." Ouch.
 




I work in big Pharma now but got contacted for a consulting position in IMS. What are the pros and cons of working for IMS vs Pharma? What is the pay like? Benefits?

Can't believe that IMS would want someone who is so clueless that he would ask a question like this. 2nd poster had it right - ask IMS, dummy!
 
















IMS remuneration for consulting is comperable with other leading consultancies... its the only way to attract and retain quality staff.

However I would recommend you steer clear, there is little real consulting going on, its mostly 'platformed' consulting based on standard processes and very little original work going on. Most of the experienced external consultants recruited to IMS tend to move on very quickly.

The powers that be expect the growth in consulting within IMS to stop in the next 18 months.
 




IMS will be out of business in less than 5 years

Their data collection was never accurate.

Big pharma has begun dropping them.
Glaxo dropped them already.
JNJ next

and several mid and small companies are slated to not renew contracts.
 




IMS will be out of business in less than 5 years

Their data collection was never accurate.

Big pharma has begun dropping them.
Glaxo dropped them already.
JNJ next

and several mid and small companies are slated to not renew contracts.

geez all you can do is cut and past this commentt to all the boards? lazy bastard
 




I work in big Pharma now but got contacted for a consulting position in IMS. What are the pros and cons of working for IMS vs Pharma? What is the pay like? Benefits?

This is why your industry is going down the drain. Idiots like this that work for the industry. IMS will fall, like SDI and Verispan. It may take quite a few years, but it will. With the decline of pharma's not wanting this "luxury" data and the cost of the SDI purchase, the ship has already sprung a small leak. It will get much much bigger.